Skip to main content
Clinical Trials/CTRI/2024/02/062947
CTRI/2024/02/062947RecruitingPhase 4

Comparative evaluation of efficacy of single pre-emptive dose of Extended release Lornoxicam versus Prolonged release Diclofenac for surgical removal of impacted 3rd molar in Indian population: A prospective, randomized, triple blind, split mouth clinical trial. - NI

Terna Dental College0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Recruiting

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Patients who are willing to participate in the study
  • 2.Patients requiring surgical extraction of bilateral impacted mandibular 3rd molar of similar difficulty (easy or moderate difficulty as per Pederson’s difficulty index)
  • 3.Healthy patients belonging to ASA Class I or II will be included
  • 4.Patients who are not on any pain management therapy or those who have not consumed any NSAID in the last seven days.

Exclusion Criteria

  • 1.Patients not willing to participate in the study
  • 2.H/o Hypersensitivity reactions to Lornoxicam, Diclofenac or any other NSAID
  • 3.Pregnant and lactating patients
  • 4.Patients suffering from Bronchial Asthma or COPD or bleeding diathesis.
  • 5.Patients with H/o gastritis, gastric/ duodenal ulcers, or any other inflammatory gastrointestinal disease
  • 6.Pederson difficulty index score 7-10 (Difficult)
  • 7.Patients having local signs of infection around the impacted tooth to be removed such as periapical abscess/granuloma, pericoronal abscess, fascial space infection etc.

Investigators

Similar Trials